Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Mar 20;6(5):531-6.
doi: 10.1021/acsmedchemlett.5b00025. eCollection 2015 May 14.

Discovery of a Potent Class of PI3Kα Inhibitors with Unique Binding Mode via Encoded Library Technology (ELT)

Hongfang Yang  1 , Patricia F Medeiros  1 , Kaushik Raha  2 , Patricia Elkins  2 , Kenneth E Lind  1 , Ruth Lehr  2 , Nicholas D Adams  2 , Joelle L Burgess  2 , Stanley J Schmidt  2 , Steven D Knight  2 , Kurt R Auger  2 , Michael D Schaber  2 , G Joseph Franklin  1 , Yun Ding  1 , Jennifer L DeLorey  1 , Paolo A Centrella  1 , Sibongile Mataruse  1 , Steven R Skinner  1 , Matthew A Clark  1 , John W Cuozzo  1 , Ghotas Evindar  1
Affiliations

Discovery of a Potent Class of PI3Kα Inhibitors with Unique Binding Mode via Encoded Library Technology (ELT)

Hongfang Yang et al. ACS Med Chem Lett. .

Abstract

In the search of PI3K p110α wild type and H1047R mutant selective small molecule leads, an encoded library technology (ELT) campaign against the desired target proteins was performed which led to the discovery of a selective chemotype for PI3K isoforms from a three-cycle DNA encoded library. An X-ray crystal structure of a representative inhibitor from this chemotype demonstrated a unique binding mode in the p110α protein.

Keywords: ELT; Encoded Library technology; PI3K p110α (H1047R); PI3Kα; p110α.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interest.

Figures

Figure 1
Figure 1
Design of DEL-A: “null” indicates that the reaction was carried out without addition of the desired BB amino acid (R1) or boronate (R2).
Figure 2
Figure 2
PI3Kα wild type selection (left), mutant (H1047R) selection (middle), and mutant selection with ZSTK474competitor (right). Library members with a single copy were removed to simplify visualization.
Scheme 1
Scheme 1. Selected Building Blocks at Cycle 3 (1) and Cycle 2 (2, 3, and 4)
Scheme 2
Scheme 2. Inhibitor Pharmacophore Defined by Selection Analysis
Scheme 3
Scheme 3. Synthesis of the Target Off-DNA Compounds
Figure 3
Figure 3
X-ray structure of 5e bound to PI3Kα: (a) key interactions of the inhibitor in the active site depicted; (b) surface representation of the active site with the bound inhibitor demonstrates steric packing and interactions with the residues of the P-loop.
See this image and copyright information in PMC

References

    1. Frantz S. 2003 Approvals: a year of innovation and upward. Trends. Nat. Rev. Drug Discovery 2004, 3, 103–105. - PubMed
    1. Brown D. Unfinished business: target-based drug discovery. Drug Discovery Today 2007, 12, 1007–1012. - PubMed
    1. Payne D. J.; Gwynn M. N.; Holmes D. J.; Pompliano D. L. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discovery 2007, 6, 29–40. - PubMed
    1. First DNA-based bead-encoding strategy proposed byBrenner S.; Lerner R. A. Encoded combinatorial chemistry. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 5381–5383. - PMC - PubMed
    1. Franzini R. M.; Neri D.; Scheuermann J. Acc. Chem. Res. 2014, 47, 1247–1255. - PubMed

LinkOut - more resources